Drug Patents Expiring in 2038

1. Drug name - ADHANSIA XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10722473 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Nov, 2038

(16 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
35MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
45MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
55MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
70MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
85MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

2. Drug name - AIRDUO DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000653 TEVA PHARM Inhaler Dec, 2038

(16 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.113MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.232MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription

3. Drug name - ALTRENO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10653656 DOW PHARM Topical pharmaceutical compositions for treating skin conditions Aug, 2038

(15 years from now)

Drugs and Companies using TRETINOIN ingredient

Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older

Dosage: LOTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.05% LOTION;TOPICAL Prescription

4. Drug name - ARMONAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000653 TEVA PHARM Inhaler Dec, 2038

(16 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH POWDER;INHALATION Discontinued
0.113MG/INH POWDER;INHALATION Discontinued
0.232MG/INH POWDER;INHALATION Discontinued
0.03MG/INH POWDER;INHALATION Discontinued

5. Drug name - AUSTEDO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11179386 TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use Mar, 2038

(15 years from now)

US11179386

(Pediatric)

TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use Sep, 2038

(15 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Treatment: Treatment of tardive dyskinesia; a method of treating huntington's chorea

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
6MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
12MG TABLET;ORAL Prescription

6. Drug name - BALVERSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11077106 JANSSEN BIOTECH Cancer treatment Feb, 2038

(15 years from now)

Drugs and Companies using ERDAFITINIB ingredient

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 or fgfr2 genetic alterations, and progressed during or following prior platinum-containing chemotherapy, with dosing based on serum phosphate levels

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription

7. Drug name - BAQSIMI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10894133 ELI LILLY AND CO Device for dispensing a fluid product Jan, 2038

(15 years from now)

Drugs and Companies using GLUCAGON ingredient

Treatment: NA

Dosage: POWDER;NASAL

More Information on Dosage
Strength Dosage Availability
3MG POWDER;NASAL Prescription

8. Drug name - CERDELGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888544 GENZYME CORP Methods for treating Gaucher disease Dec, 2038

(16 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with moderate to severe renal impairment; long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with mild hepatic impairment and are concurrently taking a strong or moderate cyp3a inhibitor

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 84MG BASE CAPSULE;ORAL Prescription

9. Drug name - CONSENSI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350171 PURPLE BIOTECH Celecoxib and amlodipine formulation and method of making the same Jun, 2038

(15 years from now)

US10925835 PURPLE BIOTECH Celecoxib and amlodipine formulation and method of making the same Jun, 2038

(15 years from now)

US10945960 PURPLE BIOTECH Celecoxib and amlodipine formulation and method of making the same Jun, 2038

(15 years from now)

Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient

Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE;200MG TABLET;ORAL Discontinued
EQ 5MG BASE;200MG TABLET;ORAL Discontinued
EQ 10MG BASE;200MG TABLET;ORAL Discontinued

10. Drug name - COTEMPLA XR-ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11166947 NEOS THERAPS INC Effective dosing of a child for the treatment of ADHD with methylphenidate Jan, 2038

(15 years from now)

Drugs and Companies using METHYLPHENIDATE ingredient

Treatment: Treatment of attention deficit hyperactivity disorder (adhd) in pediatric patients

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
8.6MG TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
17.3MG TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
25.9MG TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription

11. Drug name - CYSVIEW KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11235168 PHOTOCURE ASA Method of photodynamic therapy (PDT) for bladder cancer Jan, 2038

(15 years from now)

Drugs and Companies using HEXAMINOLEVULINATE HYDROCHLORIDE ingredient

Treatment: Detection of carcinoma in the bladder by photodynamic cystoscopy

Dosage: FOR SOLUTION;INTRAVESICAL

More Information on Dosage
Strength Dosage Availability
100MG/VIAL FOR SOLUTION;INTRAVESICAL Prescription

12. Drug name - EMPAVELI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040107 APELLIS PHARMS Dosing regimens and related compositions and methods Apr, 2038

(15 years from now)

Drugs and Companies using PEGCETACOPLAN ingredient

Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan; treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan every three days; treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan twice weekly

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
1080MG/20ML (54MG/ML) SOLUTION;SUBCUTANEOUS Prescription

13. Drug name - ERLEADA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10702508 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer Apr, 2038

(15 years from now)

Drugs and Companies using APALUTAMIDE ingredient

Treatment: Treatment in combination with androgen deprivation therapy of non-metastatic, castration-resistant prostate cancer (nmcrpc) that improves metastasis free survival

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription

14. Drug name - FERRIPROX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940115 CHIESI Delayed release deferiprone tablets and methods of using the same Oct, 2038

(16 years from now)

US10940116 CHIESI Delayed release deferiprone tablets and methods of using the same Oct, 2038

(16 years from now)

US10780055 CHIESI Delayed release deferiprone tablets and methods of using the same Oct, 2038

(16 years from now)

Drugs and Companies using DEFERIPRONE ingredient

Treatment: Method of treating transfusional iron overload

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1GM TABLET;ORAL Prescription

15. Drug name - FINTEPLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10452815 ZOGENIX INC Control system for control of distribution of medication Jun, 2038

(15 years from now)

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Treatment: Use of cardiac monitoring and restricted distribution of fenfluramine to mitigate risk of cardiovascular toxicity in the treatment of seizures associated with dravet syndrome

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.2MG BASE/ML SOLUTION;ORAL Prescription

16. Drug name - GALAFOLD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10471053 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10806727 AMICUS THERAP US Methods of treating fabry patients having renal impairment May, 2038

(15 years from now)

US10799491 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10792279 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10792278 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10874656 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10874655 AMICUS THERAP US Methods of treating fabry patients having renal impairment May, 2038

(15 years from now)

US10874657 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10857142 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10849889 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10849890 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10857141 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10251873 AMICUS THERAP US Methods of treating fabry patients having renal impairment May, 2038

(15 years from now)

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 123MG BASE CAPSULE;ORAL Prescription

17. Drug name - GOCOVRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065213 ADAMAS PHARMA Amantadine compositions and preparations thereof Aug, 2038

(15 years from now)

US11077073 ADAMAS PHARMA Methods of using amantadine compositions Aug, 2038

(15 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; treatment of dyskinesia and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 68.5MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 137MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription

18. Drug name - INGREZZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11026939 NEUROCRINE High dosage valbenazine formulation and compositions, methods, and kits related thereto Sep, 2038

(15 years from now)

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE CAPSULE;ORAL Prescription
EQ 60MG BASE CAPSULE;ORAL Prescription
EQ 80MG BASE CAPSULE;ORAL Prescription

19. Drug name - KLISYRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10669236 ALMIRALL Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
Sep, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617693 ALMIRALL Methods of treating and/or preventing actinic keratosis Mar, 2038

(15 years from now)

Drugs and Companies using TIRBANIBULIN ingredient

Treatment: Topical treatment of actinic keratosis of the face or scalp

Dosage: OINTMENT;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% OINTMENT;TOPICAL Prescription

20. Drug name - KORLYM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10780097 CORCEPT THERAP Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients Aug, 2038

(15 years from now)

US10314850 CORCEPT THERAP Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients Aug, 2038

(15 years from now)

US10231983 CORCEPT THERAP Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients Aug, 2038

(15 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET;ORAL Prescription

21. Drug name - LEVOLET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10231931 GENUS LIFESCIENCES Thyroid hormone oral dosage forms and methods of using the same Mar, 2038

(15 years from now)

US10406108 GENUS LIFESCIENCES Thyroid hormone oral dosage forms and methods of using the same Mar, 2038

(15 years from now)

More Information on Dosage
Strength Dosage Availability
0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription

22. Drug name - LEVULAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11135293 DUSA Methods for photodynamic therapy Jan, 2038

(15 years from now)

US11077192 DUSA Methods for photodynamic therapy Jan, 2038

(15 years from now)

US10357567 DUSA Methods for photodynamic therapy Jan, 2038

(15 years from now)

Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient

Treatment: Treatment of actinic keratoses of upper extremities by photodynamic therapy

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
20% SOLUTION;TOPICAL Prescription

23. Drug name - LUMAKRAS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10519146 AMGEN INC KRAS G12C inhibitors and methods of using the same
May, 2038

(15 years from now)

EP3630761B1 AMGEN INC Kras G12C Inhibitors And Methods Of Using The Same
May, 2038

(15 years from now)

EP3630761A1 AMGEN INC Kras G12C Inhibitors And Methods Of Using The Same
May, 2038

(15 years from now)

Drugs and Companies using SOTORASIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
120MG TABLET;ORAL Prescription

24. Drug name - LUMASON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335502 BRACCO Freeze-dried formulation for gas-filled microvesicles Jul, 2038

(15 years from now)

US10232061 BRACCO Freeze-dried formulation for gas-filled microvesicles Jul, 2038

(15 years from now)

More Information on Dosage
Strength Dosage Availability
60.7MG/25MG FOR SUSPENSION;INTRAVENOUS Prescription

25. Drug name - LUTATHERA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596276 AAA USA INC Stable, concentrated radionuclide complex solutions Jul, 2038

(15 years from now)

US10596278 AAA USA INC Stable, concentrated radionuclide complex solutions Jul, 2038

(15 years from now)

Drugs and Companies using LUTETIUM DOTATATE LU-177 ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
10mCi/ML SOLUTION;INTRAVENOUS Prescription

26. Drug name - MIDAZOLAM IN 0.9% SODIUM CHLORIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10966990 INFORLIFE Midazolam in flexible bags Jun, 2038

(15 years from now)

Drugs and Companies using MIDAZOLAM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/50ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription
100MG/100ML (1MG/ML) SOLUTION;INTRAVENOUS Prescription

27. Drug name - NUBEQA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11168058 BAYER HEALTHCARE Manufacture of a crystalline pharmaceutical product
Feb, 2038

(15 years from now)

More Information on Dosage
Strength Dosage Availability
300MG TABLET;ORAL Prescription

28. Drug name - NUPLAZID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849891 ACADIA PHARMS INC Formulations of pimavanserin Aug, 2038

(15 years from now)

US10646480 ACADIA PHARMS INC Formulations of pimavanserin Aug, 2038

(15 years from now)

US10449185 ACADIA PHARMS INC Formulations of pimavanserin Aug, 2038

(15 years from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 34MG BASE CAPSULE;ORAL Prescription

29. Drug name - NYMALIZE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10576070 ARBOR PHARMS LLC Non-aqueous liquid nimodipine compositions Apr, 2038

(15 years from now)

US11207306 ARBOR PHARMS LLC Non-aqueous liquid nimodipine compositions Apr, 2038

(15 years from now)

US10342787 ARBOR PHARMS LLC Non-aqueous liquid nimodipine compositions Apr, 2038

(15 years from now)

Drugs and Companies using NIMODIPINE ingredient

Treatment: A method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry aneurysms

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
3MG/ML SOLUTION;ORAL Discontinued
6MG/ML SOLUTION;ORAL Prescription

30. Drug name - OSMOLEX ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500170 ADAMAS PHARMA Composition and method for treating neurological disease Feb, 2038

(15 years from now)

US10512617 ADAMAS PHARMA Composition and method for treating neurological disease Feb, 2038

(15 years from now)

US10213394 ADAMAS PHARMA Composition and method for treating neurological disease Feb, 2038

(15 years from now)

US10213393 ADAMAS PHARMA Composition and method for treating neurological disease Feb, 2038

(15 years from now)

US10500171 ADAMAS PHARMA Composition and method for treating neurological disease Feb, 2038

(15 years from now)

US10500172 ADAMAS PHARMA Composition and method for treating neurological disease Feb, 2038

(15 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Treatment: A process for treating a patient suffering from parkinson's syndrome and in need of treatment; Treatment of drug-induced extrapyramidal reaction in adult patients

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 129MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 161MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
EQ 193MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 258MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

31. Drug name - PROAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000653 TEVA BRANDED PHARM Inhaler Dec, 2038

(16 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH POWDER, METERED;INHALATION Prescription

32. Drug name - PYRUKYND

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11254652 AGIOS PHARMS INC Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
Nov, 2038

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234976 AGIOS PHARMS INC Methods of using pyruvate kinase activators Oct, 2038

(16 years from now)

Drugs and Companies using MITAPIVAT SULFATE ingredient

Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency by administering a daily dose of 10mg to 100mg

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 20MG BASE TABLET;ORAL Prescription
EQ 50MG BASE TABLET;ORAL Prescription

33. Drug name - RETEVMO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10584124 LOXO ONCOLOGY INC Crystalline forms
Oct, 2038

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786489 LOXO ONCOLOGY INC Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile Oct, 2038

(16 years from now)

Drugs and Companies using SELPERCATINIB ingredient

Treatment: Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is papillary thyroid cancer; the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is recurrent thyroid cancer; treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is medullary thyroid cancer; the treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer (nsclc); treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is differentiated thyroid cancer; treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive refractory differentiated thyroid cancer who require systemic therapy and are radioactive iodine-refractory

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
40MG CAPSULE;ORAL Prescription
80MG CAPSULE;ORAL Prescription

34. Drug name - ROZLYTREK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398693 GENENTECH INC Pharmaceutical compositions and dosage forms Jul, 2038

(15 years from now)

Drugs and Companies using ENTRECTINIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription
200MG CAPSULE;ORAL Prescription

35. Drug name - SOTALOL HYDROCHLORIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10512620 ALTATHERA PHARMS LLC Method of initiating and escalating sotalol hydrochloride dosing Aug, 2038

(15 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Treatment: Dosing regimen for intravenous sotalol for administration in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation.

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
150MG/10ML (15MG/ML) SOLUTION;INTRAVENOUS Prescription

36. Drug name - SUBLOCADE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646484 INDIVIOR INC Methods to treat opioid use disorder Jun, 2038

(15 years from now)

Drugs and Companies using BUPRENORPHINE ingredient

Treatment: Treatment of moderate to severe opioid use disorder

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
100MG/0.5ML (100MG/0.5ML) SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS Prescription
300MG/1.5ML (200MG/ML) SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

37. Drug name - SUNOSI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959976 JAZZ Methods and compositions for treating excessive sleepiness Jun, 2038

(15 years from now)

US10912754 JAZZ Methods and compositions for treating excessive sleepiness Jun, 2038

(15 years from now)

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa) with a dosing regimen that includes a dose of 75 mg once daily for at least 3 days followed by 150 mg once daily; Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in an adult through a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE TABLET;ORAL Prescription
EQ 150MG BASE TABLET;ORAL Prescription

38. Drug name - SYMTUZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786518 JANSSEN PRODS Compositions and methods of treating HIV Jul, 2038

(15 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: Treatment of hiv-1 infection in adult or pediatric patients (>=40 kg) with <50 copies/ml hiv-1 rna after >= 6 months on prior antiretroviral regimen and no known darunavir or tenofovir resistance-associated substitutions

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG;800MG;200MG;EQ 10MG BASE TABLET;ORAL Prescription

39. Drug name - TURALIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435404 DAIICHI SANKYO INC Formulations of a compound modulating kinases Jul, 2038

(15 years from now)

US10961240 DAIICHI SANKYO INC Formulations of a compound modulating kinases Jul, 2038

(15 years from now)

US10941142 DAIICHI SANKYO INC Formulations of a compound modulating kinases Jul, 2038

(15 years from now)

Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE CAPSULE;ORAL Prescription

40. Drug name - TWYNEO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10420743 GALDERMA LABS LP Methods and compositions for the treatment of acne Jul, 2038

(15 years from now)

Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient

Treatment: Topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
3%;0.1% CREAM;TOPICAL Discontinued

41. Drug name - TYMLOS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10996208 RADIUS HEALTH INC Abaloparatide formulations and methods of testing, storing, modifying, and using same Apr, 2038

(15 years from now)

Drugs and Companies using ABALOPARATIDE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
3.12MG/1.56ML (2MG/ML) SOLUTION;SUBCUTANEOUS Prescription

42. Drug name - VEKLURY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10675296 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections Jul, 2038

(15 years from now)

Drugs and Companies using REMDESIVIR ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription
100MG/20ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription

43. Drug name - WEGOVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888605 NOVO GLP-1 compositions and uses thereof Aug, 2038

(15 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.25MG/0.5ML (0.25MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
0.5MG/0.5ML (0.5MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
1MG/0.5ML (1MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
1.7MG/0.75ML (1.7MG/0.75ML) SOLUTION;SUBCUTANEOUS Prescription
2.4MG/0.75ML (2.4MG/0.75ML) SOLUTION;SUBCUTANEOUS Prescription

44. Drug name - XYOSTED (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646495 ANTARES PHARMA INC Testosterone ester triglyceride formulations Aug, 2038

(15 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
50MG/0.5ML (50MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
75MG/0.5ML (75MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
100MG/0.5ML (100MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription

45. Drug name - ZEJULA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11091459 GLAXOSMITHKLINE Niraparib compositions Mar, 2038

(15 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.